Dopamine Receptor Agonists and Hypertension
Dopamine receptor agonists exert pronounced cardiovascular actions that result from activation of specific dopamine receptors located at various sites within the cardiovascular system (Clark, 1981; Cavero et al., 1982a,b; Lokhandwala and Barrett, 1981, 1982, 1983). Although dopamine is the prototype of dopamine receptor agonists, in addition to the activation of dopamine receptors, this catecholamine also possesses agonistic actions at a and β adrenoceptors (Goldberg, 1972; Lokhandwala and Barrett, 1982). Therefore, attempts have been made to develop Compounds that are selective at dopamine receptors and do not exert significant actions at other adrenoceptors. As discussed in several chapters of this volume, one of the major aims in developing these compounds is for the therapeutic potential they offer in the treatment of various cardiovascular and renal disorders.
KeywordsDopamine Receptor Ergot Alkaloid Dopamine Receptor Agonist Antihypertensive Action Mean Blood Pressure
Unable to display preview. Download preview PDF.
- Barrett, R. J., and Lokhandwala, M. F., 1981a, Presynaptic dopamine receptor stimulation in the cardiovascular actions of lergotrile, J. Pharmacol. Exp. Ther. 217:660–665.Google Scholar
- Barrett, R. J., and Lokhandwala, M. F., 1981b, The role of alpha adrenergic and dopamine receptor activation in the cardiovascular effects of pergolide, Fed. Proc. 40:315.Google Scholar
- Clark, B. J., 1979, Cardiovascular effects of ergot alkaloids, J. Pharmacol. (Paris) 10:439–453.Google Scholar
- Lokhandwala, M. F., and Barrett, R. J., 1981, Pharmacological role of presynaptic dopamine receptors in the cardiovascular actions of dopaminergic agents, in: Central Nervous System Mechanisms in Hypertension (J. P. Buckley and C. M. Ferrario, eds.), Raven Press, New York, pp. 203–213.Google Scholar